Stocks · News reference
Takeda ((TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Takeda reported that its Phase 3 G-HOPE-001 study of arcotatug tavatecan (TAK-921) met its primary endpoints, demonstrating statistically significant improvements in overall survival and progression-free survival for patients with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.